yesterday lilli host financi updat meet new york newli issu
revenu ep guidanc estim consensu long-term growth
target also rais outlook newer product pipelin opportun pipelin
updat increment oppos new news takeaway detail
manag expect ep vs last-publish revenu
mid singl digit growth fx clip vs last-publish
revenu ep guidanc ahead number consensu ep guidanc includ
elanco howev separ elanco year ipo anniversari
septemb trulic alimta seem like primari driver better-than-
expect top line expect line item guidanc gpm approx help
fx sg oper margin approxim
net loss due higher interest expens tax rate approxim
think sustain share count approxim guidanc
assum elanco held updat model reflect guidanc attach
tailwind includ solid uptak newer product potenti new launch nasal
glucagon lasmiditan label expans taltz cyramza save
on-going product initi headwind includ loe impact ciali
forteo effient alimta germani increas contribut part donut hole
revenu lilli on-going price headwind neg
fx higher interest expens tough compar sizabl invest gain
prior guidanc revenu growth compound-annual-growth-rate least
manag rais least least human pharma busi alon
exclud elanco compar forecast lilli also expect oper
margin higher human pharma last publish estim
includ elanco new model still guidanc
lilli target launch nme within year date launch
verzenio olumi emgal lilli pipelin includ
candid potenti approved/launch nasal glucagon file lasmiditan
autom insulin deliveri system tirzepatid mab aura
 improv especi speed evalu first human dose launch time
acceler past sever year trial enrol much faster trial
design facilit enrol manag also indic expect util bd
includ collabor past strengthen pipelin especi earli
stage asset one-third pipelin molecul expect come bd
pleas see page report import disclosur
number promis new drug current roll hand late-stag agent
pois launch next year give us confid -averag sale
ep growth prospect estim ep compound-annual-growth-rate compar
industri averag dividend yield attract
verzenio breast cancer emgal
perform diabet busi
notabl trulic
full trulic rewind data ada
revenu growth leverag
ep growth
declin alimta
temper keytruda/chemo
one four less visibl pipelin
candid gener
margin expans sooner greater
alimta declin rapidli
margin expans delay reduc
compani global biopharmaceut compani incorpor
indiana two main segment human pharmaceut product anim health
product lead product area diabet metabol diseas oncolog
among other lilli anim health busi oper elanco anim
divis develop manufactur market product food companion
anim retain elanco post septemb ipo
trulic see continu strong growth excel access gain
share point sinc ozemp novo launch ozemp taken share novo
victoza class growth acceler well believ
still room gain full rewind cv outcom data ada
file
tirzepatid recent initi phase studi compani
also announc phase obes phase ii nash start
new titrat dosag discuss tirzepatid given increment
week work expect dose tirzepatid also administ
trulicity-lik pen expect improv patient accept expect
file
insulin ultra-rapid lispro mealtim insulin report posit data improv
glucos control comparable/low risk hypoglycemia file
manag excit basal insulin-fc new insulin weekli dose
still earli develop phase start
deliveri devic partnership deka exclus non-
exclus lilli develop connect insulin pen pump provid
variou smart solutions/app data captur capabl connect
portfolio expect launch stage start
manag see potenti verzenio growth acceler key two potenti
new indic breast cancer data phase ii monarch trial
herceptin expect earli success market would expand
potenti verzenio could also encourag greater use current
market growth slow demonstr safeti anoth
bc patient popul adjuv breast cancer phase monarch trial
enrol well patient first month total expect
data expect adjuv market estim current
emgal cgrp migrain prevent approv septemb good
payor access file acut cluster headach approv expect
cluster headach claim would differenti emgal lasmitidan would
first new medicin acut migrain treatment year file
approv expect
tanezumab ngf pain await safeti data trial studi
week efficaci safeti studi oa studi long term efficaci
safeti trial oa studi chronic lower back pain clbp efficaci data
promis seen week dose trial report juli safeti
primarili concern rpoa key futur prospect lilli remain
optimist role non-opioid pain reliev tanezumab
econom split
olumi baricitinib approv countri ra manag indic
feedback dose oa approv ou
posit dose current evalu atop dermat phase top
line data expect alopecia areata data sle phase top line
expect track design manag expect olumi first jak
commerci atop dermat alopecia areata compani also indic
discuss fda regard dose ra detail
pegilodecakin acquir part armo june current phase ii
trial nsclc top line data expect late phase
pancreat cancer w/folfox top-lin data indic may
evalu includ io-refractori nsclc rcc phase ii start pancreat
cancer tumor type lilli believ strong biolog rational
pegilodecakin increas intra-tumor cell distinct mechan io
reduct inflammatori cytokin respons may impact mani cancer
mirikizumab anti phase psoriasi data expect phase ii
pasi pasi strong howev lilli believ key indic
mirikizumab uc crohn phase ii uc start data
expect mirikizumab phase ii crohn data expect
phase initi lilli seek develop mirikizumab best class
taltz best
antibodi phase data mono combo therapi arora
kinas inhibitor phase data tumor rb loss myc amplif and/or
aura overexpress focu prexasertib inhibitor potenti dna
repair defect activ brca wt high grade ovarian cancer phase ii data
alzheim lilli abeta antibodi phase ii earli alzheim
amyloid posit low-medium tau burden enrol expect complet
readout primari endpoint function iadr integr
alzheim diseas rate scale month anti- tau antibodi also
develop phase ii earli symptomat alzheim low-medium tau
burden primari endpoint iadr data expect parkinson lilli
pam posit alloster modul phase ii mild-to-moder
parkinson dementia data expect
compani data cowen compani
grosssg ar dop non-pretaxtaxnetepssharessal chgp mm sl mm slsp opp rateincom dil restat pension account rule chang cowen
compani data cowen compani
productstrul europ lc ex europ lc ex europ lc ex europ lc ex world-wide share europ lc ex world-wide share cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
drug continuedreopro europ lc ex europ lc ex fx axiron europ lc ex antibiot inject antibiot europ lc ex europ lc ex drug healthfood cowen
compani data cowen compani
end market sale euro end market sale world-wide share end market sale euro end market sale world-wide share cowen
compani data cowen compani
growth productstrul us share novo competit manageabletrul europ lc ex fx -australia europetrul eu emerg marketstrul qweek dose type diabet rewind cv studi posit data ada higher dose phase expir biosimilar launch new modal anticipatedforteo europ lc ex fx -australia europeforteo expir biosimilar launch anticipatedforteo expir biosimilar launch anticipatedforteo emerg marketsforteo hormon osteoporosi two year durat treatmentcyramza pressur io target agentscyramza europ lc ex fx -australia europecyramza nsclc cyramza uptak gastriccyramza emerg marketscyramza ramu app gastric lung file ph lungjardi us empa-reg cv outcom studi reflect label heart failur studi underwayjardi europ lc ex fx -australia europejardi eu empa-reg data file file jardiance/trajenta nda eujardi japanjardi emerg market approv chinajardi world-wide share inhibitor share gross profit w/bi reflect revenue incl glyxambi synjardi hf type diabet ptrajenta market share patent expir europ lc ex fx -australia europetrajenta patent expir patent expir emerg marketstrajenta world-wide share inhibitor cv outcom data expect share gross profit bi reflect revenu cowen
compani data cowen compani
new drugstaltz psoriasi market share competit landscap evolv rapidlytaltz europ lc ex fx taltz eu mod/sever psoriasi taltz phase axspa radiograph non-radiograph basaglar/abasria settlement w/sni allow launch strong launchbasaglar/abasria europ lc ex fx basaglar/abasria market eubasaglar/abasria countri basaglar/abasria insulin glargin diabet lantu biosimilar expectedglucagon europ lc ex fx gucagon hypoglycemia intranas filedadcirca launch spetmeb europ lc ex fx adcirca pulmonari arteri hypertensionlartruvo soft tissu sarcoma europ lc ex fx lartruvo phase ii pancreat cancer pdgf alpha inhib approv eu/japan mbc adjuv bc inhib ra launch eu japan atop derm sle alopecia areata cgrp mab market episod chronic migrain cluster ha data oral human ant-egfr fda approv line squamou nsclc launch eu cowen
compani data cowen compani
new drug sever pain cancer pain oa pain clbp phase safeti data key tx studi posit file oral altern deliveri consid via colucid diagnost tau imag agent phase data rapid act phase dm develop producttgf beta phase amylin calcitonin receptor agonist diabet phase ulcer coliti phase psoriasi phase crohn diseas phase phase iitau deposit diseas phase iibtk phase inhibitor phase inhibitor small molecul cancer phase ii tier develop clarifi data expect sever kinas phase pancreat cancer lung rcc melanoma solid tumor earlier phase phase diseas phase iierbitux revenu erbitux sale full right close royalti europ lc ex fx -australia europeerbitux royalti report ou revenu key greater transpar drug solderbitux royalti royalti kgaa asset due fulli paid licenseerbitux royalti growth new drug sale drugsalimta exp pedi extens vitamin supplement patent prevail appeal pto deni ipr vitamin supplement patent approv use keytruda nsclcalimta europ lc ex fx -australia europealimta exp vitamin supplement patent til eu upheld eu gener francealimta exp method-of-us patent eu alimta emerg marketsalimta synthetas inhib mesothelioma nscl io/target agent impact nsclc usageciali expir pedi exclus pend patent litig settlement allow gener launch gener sildenafil pressuringciali europ lc ex fx -australia europeciali expir expir emerg marketsciali bphhumatrop europ lc ex fx -australia europehumatrop emerg marketshumatrop cowen
compani data cowen compani
establish drug continuedeffi expir includ pedi exclus effient europ lc ex fx -australia europeeffi expir emerg marketseffi trilog medic mgd patient accoast pre-tx trigger drug elut stent miss endpointsevista expir multipl gener soldevista europ lc ex fx -australia europeevista expir expir emerg marketsevista breast cancer preventioncymbalta expir multipl gener soldcymbalta europ lc ex fx -australia europecymbalta exclus expir gener launch mid expir emerg marketscymbalta pain gad fibromyalgia chronic painzyprexa expir author gener sale book herezyprexa europ lc ex fx -australia europezyprexa expir expir gener launch emerg marketszyprexa strattera expir europ lc ex fx -australia canada europestrattera expir emerg marketsstrattera deficit hyperactivityprozac europ lc ex fx -australia europeprozac competitionprozac emerg marketsprozac europ lc ex fx -australia europegemzar emerg marketsgemzar nsclc bladder breast ovarian gener cowen
compani data cowen compani
establish drug continuedreopro europ lc ex fx -australia europereopro emerg marketsreopro mix view competit productsaxiron launchedaxiron europ lc ex fx axiron topic solut agreement acrux market eu pursu chf market foreign europ lc ex europeacto emerg marketsacto foreign market pay royalti sale otcor cd outlicens dura antibiot focusinject inject antibiot market share sni biosimilar rcv approv europ lc ex fx -australia europehumalog biosimilar approv eu emerg marketshumalog act insulin patent expir europ lc ex fx -australia europehumulin emerg marketshumulin patent protectionoth productsinsulin hyperlipidemia kowa latin american right retain right patent expir intern product beirsdorf german drug manuf establish drug drug sale new product healthfood nv acquisit close addit jansen sales/yr lohmann sales/yr sales/yr total equiti model assum remaind retainedy/i industri averagey/i cowen
compani data cowen compani
trajenta end market sale euro rate end market sale world-wide share inhibitor cv outcom data expect share gross profit bi reflect revenuejardi end market sale euro rate end market sale world-wide share inhibitor share gross profit w/bi reflect revenue incl glyxambi synjardi hf piii type diabet piii cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl diabet portfolio
success pipelin product especi ramucirumab dulaglutid success
deal patent litig patent expir pressur uncertainti strateg
direct could includ outlook dividend greater expect
competit diabet affect franchis macro factor lessen appeal
